Bortezomib maintenance after R-CHOP, cytarabine and autologous stem cell transplantation in newly diagnosed patients with mantle cell lymphoma, results of a randomised phase II HOVON trial
Doorduijn, Jeanette K; Zijlstra, Josee M; Lugtenburg, Pieternella J; Kersten, Marie Josee; Böhmer, Lara H; Minnema, Monique C; MacKenzie, Marius A; van Marwijk Kooij, Rien; de Jongh, Eva; Snijders, Tjeerd J F; de Weerdt, Okke; van Gelder, Michel; Hoogendoorn, Mels; Leys, Rineke B L; Kibbelaar, Robby E; de Jong, Daphne; Chitu, Dana A; Van't Veer, Mars B; Kluin-Nelemans, Hanneke C
(2020) British Journal of Haematology, volume 190, issue 3, pp. 385 - 393
(Article)
Abstract
Rituximab-containing induction followed by autologous stem cell transplantation (ASCT) is the standard first-line treatment for young mantle cell lymphoma patients. However, most patients relapse after ASCT. We investigated in a randomised phase II study the outcome of a chemo-immuno regimen and ASCT with or without maintenance therapy with bortezomib. Induction
... read more
consisted of three cycles R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone), two cycles high-dose cytarabine, BEAM (carmustine, etoposide, cytarabine, melphalan) and ASCT. Patients responding were randomised between bortezomib maintenance (1·3 mg/m2 intravenously once every 2 weeks, for 2 years) and observation. Of 135 eligible patients, 115 (85%) proceeded to ASCT, 60 (44%) were randomised. With a median follow-up of 77·5 months for patients still alive, 5-year event-free survival (EFS) was 51% (95% CI 42-59%); 5-year overall survival (OS) was 73% (95% CI 65-80%). The median follow-up of randomised patients still alive was 71·5 months. Patients with bortezomib maintenance had a 5-year EFS of 63% (95% CI 44-78%) and 5-year OS of 90% (95% CI 72-97%). The patients randomised to observation had 5-year PFS of 60% (95% CI, 40-75%) and OS of 90% (95% CI 72-97%). In conclusion, in this phase II study we found no indication of a positive effect of bortezomib maintenance after ASCT.
show less
Download/Full Text
Keywords: Mantle cell lymphoma, bortezomib, cytarabine, maintenance therapy, phase II trial, randomised, Hematology, Journal Article
ISSN: 0007-1048
Publisher: Wiley-Blackwell
Note: Publisher Copyright: © 2020 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd
(Peer reviewed)